news
Arrowhead Subcutaneous Shot Cuts Spinal Fluid Tau by 73% in Humans
Arrowhead Pharmaceuticals reported that its subcutaneous RNAi drug slashed cerebrospinal fluid tau by 73% in healthy human volunteers. The therapy crossed the blood-brain barrier without requiring direct spinal injection or surgical delivery. For anyone tracking Alzheimer's prevention, silencing tau with a standard under-the-skin jab marks a serious shift in central nervous system medicine.
Arrowhead Pharmaceuticals reported that its subcutaneous RNAi drug slashed cerebrospinal fluid tau by 73% in healthy human volunteers. The therapy crossed the blood-brain barrier without requiring direct spinal injection or surgical delivery. For anyone tracking Alzheimer's prevention, silencing tau with a standard under-the-skin jab marks a serious shift in central nervous system medicine.
The architecture take
Getting large molecules past the blood-brain barrier usually means an intrathecal tap (a long needle straight into your spine). I used to think targeted RNA therapies for the central nervous system were ten years away from routine clinic use. Arrowhead showed that an under-the-skin jab can carry RNA interference past the brain's vascular wall and drop tau in spinal fluid by 73%. Delivery was always the bottleneck. Tau tangles drive neurodegeneration and fuel chronic neuroinflammation, but clearing them stalled because getting drugs into brain tissue was brutal. I watched neurology chase amyloid clearance for a decade while tau quietly wrecked synaptic transmission. If this knockdown holds without safety red flags in larger cohorts, the preventative brain health sector shifts completely. Biopharma will scramble to license this delivery chemistry for other targets like alpha-synuclein. I still want to see long-term cognitive testing, but crossing that barrier isn't a small feat.